Cartesian Therapeutics (RNAC) Revenue (2015 - 2026)
Cartesian Therapeutics (RNAC) reported Revenue of $78000.0 for Q1 2026, down 92.91% year-over-year from $1.1 million in Q1 2025, and up 105.38% on a QoQ basis from -$1.4 million in Q4 2025.
Cartesian Therapeutics (RNAC) has 12 years of Revenue data on file, last reported at $78000.0 in Q1 2026.
- Quarterly Revenue fell 92.91% year-over-year to $78000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$920000.0 (down 102.76% YoY) and the FY2025 annual result came in at $400000.0, down 98.95% from the prior year.
- Revenue grew to $78000.0 in Q1 2026 per RNAC's latest filing, from -$1.4 million in the prior quarter.
- Across five years, Revenue topped out at $39.3 million in Q2 2022 and bottomed at -$1.4 million in Q4 2025.
- The 5-year median for Revenue is $5.9 million (2023), against an average of $10.9 million.
- Peak annual rise in Revenue reached 533.85% in 2024, while the deepest fall reached 116.9% in 2024.
- Tracing RNAC's Revenue over 5 years: stood at $16.8 million in 2022, then sank by 50.78% to $8.3 million in 2023, then sank by 116.9% to -$1.4 million in 2024, then fell by 3.79% to -$1.4 million in 2025, then soared by 105.38% to $78000.0 in 2026.
- Per Business Quant, the three latest RNAC Revenue figures stand at $78000.0 (Q1 2026), -$1.4 million (Q4 2025), and $452000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Cartesian Therapeutics | 202.49 Mn | 202.49 Mn | - | 78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78,000.00 |
| Dec 31, 2025 | -1.45 Mn |
| Sep 30, 2025 | 452,000.00 |
| Mar 31, 2025 | 1.10 Mn |
| Dec 31, 2024 | -1.40 Mn |
| Sep 30, 2024 | 387,000.00 |
| Jun 30, 2024 | 33.27 Mn |
| Mar 31, 2024 | 5.84 Mn |
| Dec 31, 2023 | 8.27 Mn |
| Sep 30, 2023 | 6.55 Mn |
| Jun 30, 2023 | 5.25 Mn |
| Mar 31, 2023 | 5.94 Mn |
| Dec 31, 2022 | 16.80 Mn |
| Sep 30, 2022 | 20.71 Mn |
| Jun 30, 2022 | 39.27 Mn |
| Mar 31, 2022 | 34.00 Mn |
| Dec 31, 2021 | 29.94 Mn |
| Sep 30, 2021 | 24.43 Mn |
| Jun 30, 2021 | 19.66 Mn |
| Mar 31, 2021 | 11.05 Mn |
| Dec 31, 2020 | 11.95 Mn |
| Sep 30, 2020 | 4.65 Mn |
| Dec 31, 2019 | 6.65 Mn |
| Jun 30, 2019 | 13,000.00 |
| Mar 31, 2019 | 10,000.00 |
| Dec 31, 2018 | 903,000.00 |
| Dec 31, 2017 | 17,000.00 |
| Sep 30, 2017 | 27,000.00 |
| Jun 30, 2017 | 26,000.00 |
| Mar 31, 2017 | 137,000.00 |
| Dec 31, 2016 | 2.93 Mn |
| Sep 30, 2016 | 1.05 Mn |
| Jun 30, 2016 | 2.02 Mn |
| Mar 31, 2016 | 2.09 Mn |
| Dec 31, 2015 | 2.13 Mn |
| Sep 30, 2015 | 1.61 Mn |
| Jun 30, 2015 | 1.24 Mn |